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Resistance to oseltamivir was observed in inﬂ  uenza 
A pandemic (H1N1) 2009 virus isolated from an untreated 
person in Hong Kong, China. Investigations showed a re-
sistant virus with the neuraminidase (NA) 274Y genotype in 
quasi-species from a nasopharyngeal aspirate. Monitoring 
for the naturally occurring NA 274Y mutation in this virus is 
necessary.
E
mergence of inﬂ  uenza A pandemic (H1N1) 2009 virus, 
presumably from swine to humans, has spread glob-
ally since April 2009 (1–3). This emergence prompted the 
World Health Organization to declare a pandemic caused 
by this virus on June 11, 2009. Although most cases of in-
fection are mild or asymptomatic, 1,462 fatal cases were 
reported to the World Health Organization as of August 6, 
2009 (www.who.int/csr/don/2009_09_11/en/index.html). 
Experimental evidence from animal models showed 
that this virus was able to replicate to high titers in the lungs 
of infected animals (4), unlike seasonal inﬂ  uenza viruses, 
which mainly infect the upper respiratory tract. Serologic 
studies found that antibodies induced by current seasonal 
inﬂ  uenza vaccines show little cross-reactivity to pandemic 
(H1N1) 2009 virus (5).
Therapeutic options are presently limited to 2 
neuraminidase (NA) inhibitors, oseltamivir and zanamivir, 
because this virus has a swine-origin matrix 2 (M2) gene, 
which contains a mutation associated with resistance to 
M2 ion channel blockers amantadine and rimantadine. Al-
though oseltamivir has been widely used in persons infect-
ed with pandemic (H1N1) 2009 virus, resistance was not 
observed until recently. Three unrelated cases of resistance 
to oseltamivir were observed in Denmark, Japan, and Hong 
Kong (www.who.int/csr/disease/swineﬂ  u/notes/h1n1_anti
viral_resistance_20090708/en/index.html).
Emergence of resistance to oseltamivir by seasonal in-
ﬂ  uenza A virus (H1N1) was detected in Norway in 2007. 
This virus has evolved into the dominant inﬂ  uenza A virus 
(H1N1) in humans (6). This ﬁ  nding raises strong concerns 
that the 274Y resistant mutation in pandemic (H1N1) 2009 
virus might circulate and become dominant. We report vi-
rologic investigation of the emergence of oseltamivir resis-
tance in this virus in a patient from Hong Kong.
The Study
A 16-year-old previously healthy girl had a fever at 
the Hong Kong International Airport after her arrival from 
San Francisco, California, USA, on June 11, 2009. Physical 
examination showed a temperature of 38.3°C, a blood pres-
sure of 117/66 mm Hg, a pulse rate of 94 beats/min, and an 
oxygen saturation of 99% at room air. Results of a com-
plete blood count and liver and renal function tests were 
normal. She had a leukocyte count of 4.69 × 109 cells/L, an 
absolute neutrophil count of 2.36 × 109 cells/L, and a lym-
phocyte count of 1.74 × 109 cells/L. Findings on her chest 
radiograph were normal.
A nasopharyngeal aspirate (NPA) was positive for 
inﬂ  uenza A virus (H1N1) nucleoprotein by immunoﬂ  uo-
rescence. NPA specimens on days 1 and 5 were positive 
for inﬂ  uenza A virus (H1N1) M gene and swine-speciﬁ  c 
speciﬁ  c H1 gene by reverse transcription–PCR (RT-PCR). 
Samples obtained on days 6–8 were negative. Serum and 
midstream urine specimens obtained on day 2 were nega-
tive for inﬂ  uenza A virus (H1N1) M gene by RT-PCR. 
The patient refused antiviral therapy with oseltamivir 
because of fear of its potential side effects. She was then of-
fered symptomatic treatment. Her clinical condition gradual-
ly improved and she was discharged on day 8 uneventfully.
Inﬂ  uenza A pandemic (H1N1) 2009 virus was cultured 
from NPA. Subsequent drug susceptibility testing showed 
that this isolate was resistant to oseltamivir (50% inhibitory 
concentration 197.5 nM), but susceptible to zanamivir, as 
determined by enzymatic assay (Table).
To conﬁ   rm whether the virus contained mutations 
associated with resistance to NA inhibitors, NA se-
quences from the day 1 NPA specimen and an MDCK 
cell isolate were examined. Viral RNA was extracted 
from NPA and MDCK cell supernatants by using re-
ported procedures (7). RT-PCR was performed by using 
primers spanning position 274 of the NA gene (forward: 
5′-ACACAAGAGTCTGAATGTGCATGT-3′; reverse: 
5′-GTCTCCGAAAATCCCACTGCATAT-3′). Direct se-
quencing of PCR products was performed by using a Big-
Dye Terminator v3.1 cycle sequencing reaction kit on an 
ABI PRISM 3730 DNA analyzer (Applied Biosystems, 
Foster City, CA, USA).
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Sequences indicated that the NA genes in the NPA and 
MDCK cell virus isolates contained an H→Y mutation at 
the NA 274 (H3 numbering, 275 in H1 numbering) residue 
(GenBank accession no. GQ351316). No other NA muta-
tions known to be associated with oseltamivir resistance 
were observed. Further examination of sequences showed 
mixed populations (T/C) in the NA gene from the NPA 
specimen (Figure, panel A).
Estimation of 274H and 274Y populations in the NPA 
specimen was performed by cloning and sequencing PCR 
products. The NPA specimen contained approximately 
equal proportions of 274Y and 274H (52.63% and 47.37%, 
respectively). Examination of sequences from the MDCK 
cell isolate showed predominantly the 274Y type, although 
a minor 274H peak was also observed (Figure, panel B). 
Cloning and sequencing of PCR products from the MDCK 
virus isolate showed that 97.92% of the NA genes were 
274Y, which suggests that the 274Y population overtook 
the 274H population during MDCK cell culture.
Conclusions
Resistance to NA inhibitors among seasonal strains of 
human inﬂ  uenza viruses (A/H1N1, A/H3N2, and B) has 
been rare until recently. Development of resistance after os-
eltamivir treatment has occurred in 0.33%–5.5% of treated 
patients (8). Oseltamivir resistance associated with the NA 
274Y genotype was also observed in human infections with 
avian inﬂ  uenza A virus (H5N1) (9,10). Low levels of 274Y 
quasi-species in avian inﬂ  uenza A viruses (H5N1) from 
avian hosts has been reported (11). Oseltamivir-resistant 
human inﬂ  uenza A viruses (H3N2 and H1N1) have been 
found to replicate less efﬁ  ciently than oseltamivir-suscepti-
ble strains in cell culture and animal models (12–14). How-
ever, the NA 274Y resistant mutant in highly pathogenic 
avian inﬂ  uenza A virus (H5N1) retained the high pathoge-
nicity of wild-type virus in mammalian species (15).
In 2007, an NA H274Y oseltamivir-resistant variant of 
seasonal inﬂ  uenza A virus (H1N1) was detected in Norway 
(6). This virus has now become the dominant virus popula-
tion globally, overtaking oseltamivir-susceptible inﬂ  uenza 
A virus (H1N1). The molecular basis for the 274Y variant 
in seasonal inﬂ  uenza A virus (H1N1) virus and the mecha-
nism by which this resistant variant became the dominant 
population remain unknown.
Lack of general immunity to pandemic (H1N1) 2009 
virus in the human population, combined with the inher-
ent adamantane resistance of the virus, indicates that NA 
inhibitors constitute the primary treatment regimen for 
susceptible patient groups and those in whom severe dis-
eases develop during the current pandemic. There is great 
concern that an oseltamivir-resistant variant of pandemic 
(H1N1) 2009 virus may emerge and circulate in a manner 
similar to oseltamivir-resistant seasonal inﬂ  uenza A virus 
(H1N1).
The patient in this study was not treated with oselta-
mivir. Therefore it is unlikely that the 274Y mutation was 
drug-induced. Detection of mixed populations of 274Y and 
274H in the NPA specimen before antiviral treatment sug-
gests that the mutation occurs naturally, either before or 
during infection. Although no experimental data exist that 
show the growth properties of this resistant variant, exami-
nation of the quasi-species population in the cell culture–
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Table. Quasi-species of 274H and 274 Y pandemic (H1N1) 2009 virus from NPA samples and subsequent virus isolate A/Hong 
Kong/2369/2009 from MDCK cells conferring resistance to oseltamivir, Hong Kong, China* 
Sample
274H, no. samples 
positive/no. tested (%) 
274Y, no. samples 
positive/no. tested (%)  IC50 for oseltamivir, nM  IC50 for zanamivir, nM 
NPA 45/95 (47.37)  50/95 (52.63)  ND ND
MDCK cell culture  2/96 (2.08)  94/96 (97.92)  197.5 0.8
*50% inhibitory concentrations (IC50s) for oseltamivir and zanamivir were determined by using NA-Star influenza neuraminidase (NA) inhibitor resistance 
detection kits (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s instructions. Ratios of 274H and 274Y were evaluated by 
cloning neuraminidase (NA) gene PCR products from nasopharyngeal aspirate (NPA) samples or MDCK cell–cultured virus into the TA vector (Invitrogen, 
Carlsbad, CA, USA) and sequencing clones containing the NA gene. ND, not done. 
Figure. Neuraminidase (NA) 274Y (H3 subtype numbering) gene 
mutation in inﬂ   uenza A pandemic (H1N1) 2009 virus A/Hong 
Kong/2369/2009 isolated from a patient who arrived in Hong Kong, 
China, from San Francisco, California, USA, on June 11, 2009. A) 
NA sequence of virus ampliﬁ  ed by reverse transcription–PCR and 
sequenced directly from a day 1 specimen of a nasopharyngeal 
aspirate from the patient. B) NA sequence of virus grown in MDCK 
cells. Nucleotide sequence represents identiﬁ  cation of nucleotides 
by the sequencing machine, and the sequence trace represents 
the signal (peak) of each nucleotide in the sequencing reaction. 
Nucleotide coordinates (812 and 827) refer to the NA gene 
sequence of pandemic (H1N1) 2009 virus. Residue 274Y encoded 
by the 3-nucleotide codon is indicated in boxes and the nucleotide 
substitution (C→T for amino acid change H→Y) is indicated by 
arrows  Colors of curves match those of speciﬁ  c nucleotides.propagated virus isolate showed that the 274Y variant has 
become the dominant population. This ﬁ  nding implies that 
the 274Y mutation does not compromise replication of 
pandemic (H1N1) 2009 virus in vitro.
Quarantine procedures adopted by the Hong Kong 
Special Administrative Region in China during the early 
containment phase might have limited transmission of this 
variant virus. Knowledge of this virus is still limited, and 
characterization of transmission properties of this resistant 
variant in in vitro and in vivo models is needed. Moreover, 
pandemic (H1N1) 2009 virus should be closely monitored 
for emergence of resistant variants.
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